Cargando…

The Role of Multigene Assays in Addressing Treatment Heterogeneity for Breast Cancer

Breast cancer has a complex biology with heterogeneous treatment approaches that have changed significantly over the last two decades. The MAGIC survey provides valuable insight into worldwide treatment recommendations for early breast cancer patients and the clinical and pathologic criteria used fo...

Descripción completa

Detalles Bibliográficos
Autor principal: Aapro, Matti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945949/
https://www.ncbi.nlm.nih.gov/pubmed/31988928
http://dx.doi.org/10.1159/000481247
_version_ 1783485267239239680
author Aapro, Matti
author_facet Aapro, Matti
author_sort Aapro, Matti
collection PubMed
description Breast cancer has a complex biology with heterogeneous treatment approaches that have changed significantly over the last two decades. The MAGIC survey provides valuable insight into worldwide treatment recommendations for early breast cancer patients and the clinical and pathologic criteria used for these decisions. The overall findings indicate that there is substantial heterogeneity in how patients are treated and a substantial uncertainty in treatment recommendations for a large proportion of patients, highlighting an unmet need for broadly available markers, such as multigene assays, that can help to make more informed treatment decisions by predicting a patient's likelihood of benefit from adjuvant chemotherapy.
format Online
Article
Text
id pubmed-6945949
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-69459492020-01-27 The Role of Multigene Assays in Addressing Treatment Heterogeneity for Breast Cancer Aapro, Matti Biomed Hub Commentary Breast cancer has a complex biology with heterogeneous treatment approaches that have changed significantly over the last two decades. The MAGIC survey provides valuable insight into worldwide treatment recommendations for early breast cancer patients and the clinical and pathologic criteria used for these decisions. The overall findings indicate that there is substantial heterogeneity in how patients are treated and a substantial uncertainty in treatment recommendations for a large proportion of patients, highlighting an unmet need for broadly available markers, such as multigene assays, that can help to make more informed treatment decisions by predicting a patient's likelihood of benefit from adjuvant chemotherapy. S. Karger AG 2017-11-21 /pmc/articles/PMC6945949/ /pubmed/31988928 http://dx.doi.org/10.1159/000481247 Text en Copyright © 2017 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Commentary
Aapro, Matti
The Role of Multigene Assays in Addressing Treatment Heterogeneity for Breast Cancer
title The Role of Multigene Assays in Addressing Treatment Heterogeneity for Breast Cancer
title_full The Role of Multigene Assays in Addressing Treatment Heterogeneity for Breast Cancer
title_fullStr The Role of Multigene Assays in Addressing Treatment Heterogeneity for Breast Cancer
title_full_unstemmed The Role of Multigene Assays in Addressing Treatment Heterogeneity for Breast Cancer
title_short The Role of Multigene Assays in Addressing Treatment Heterogeneity for Breast Cancer
title_sort role of multigene assays in addressing treatment heterogeneity for breast cancer
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945949/
https://www.ncbi.nlm.nih.gov/pubmed/31988928
http://dx.doi.org/10.1159/000481247
work_keys_str_mv AT aapromatti theroleofmultigeneassaysinaddressingtreatmentheterogeneityforbreastcancer
AT aapromatti roleofmultigeneassaysinaddressingtreatmentheterogeneityforbreastcancer